OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Borad on the Use of Next-Generation FGFR Inhibitors in Cholangiocarcinoma and Urothelial Carcinoma

February 2nd 2023

Mitesh J. Borad, MD, discusses the unique mechanism of action of next-generation FGFR inhibitors like KIN-3248 and their potential effect on patient outcomes in cholangiocarcinoma and urothelial cancer.

Dr. Siegel on Updated Results From the KarMMA-2 Trial in R/R Multiple Myeloma

February 2nd 2023

David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.

Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple Myeloma

February 2nd 2023

Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.

Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC

February 2nd 2023

Roy S. Herbst, MD, PhD, discusses the significance of the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer.

Dr. Moghanaki on Remaining Questions Following the CheckMate-816 Trial in NSCLC

February 1st 2023

Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.

Dr. Ramnaraign on the Evaluation of Atezolizumab Plus Tivozanib in GI Malignancies

February 1st 2023

Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.

Dr. Costa on the Efficacy of Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage TNBC

February 1st 2023

Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.

Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCL

February 1st 2023

Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.

Dr. Gandhi on Key Interim Results From the SGN35-027 Trial in Hodgkin Lymphoma

February 1st 2023

Mitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.

Dr. Fakih on Tumor Microenvironment Differences in MSS mCRC

February 1st 2023

Marwan G. Fakih, MD, discusses a comparative analysis of the tumor microenvironment in primary tumors vs metastatic tissue in patients with microsatellite stable metastatic colorectal cancer.

Dr. Hecht on the Investigation of XL092/Atezolizumab in MSS/MSI-L mCRC

February 1st 2023

J. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.

Dr. Hochster on Trastuzumab/Pertuzumab Vs Cetuximab/Irinotecan in HER2-Amplified mCRC

February 1st 2023

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.

Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBC

January 31st 2023

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Dr. Chavez Mac Gregor on Key Results From SWOG S1207 in HR+/HER2- Breast Cancer

January 31st 2023

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer

January 31st 2023

Daniel King, MD, PhD, discusses socioeconomic disparities causing delays in germline genetic testing for patients with pancreatic cancer.

Dr. Cohen on the Timing of ctDNA Testing in Resected Stage I-III CRC

January 31st 2023

Stacey A. Cohen, MD, discusses the investigation of the optimal timing to test for circulating tumor DNA to detect minimal residual disease following surgery in patients with stage I to III colorectal cancer.

Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal Adenocarcinoma

January 31st 2023

Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.

Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine Neoplasms

January 31st 2023

Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.

Dr. Kishan on the MIRAGE Trial of MRI-Guided SBRT in Prostate Cancer

January 30th 2023

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple Myeloma

January 30th 2023

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.